STINGVAX (ML-RR-S2-CDA) is believed to be the first cancer vaccine to utilize a STING agonist as an adjuvant, which comprises cancer cells secreting granulocyte-macrophage colony-stimulating factor and ADU-S100 (22). Here, STING1 is linked to cancer.